We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells advises Myriad Genetics on the acquisition of Cologne-based Sividon Diagnostics

07 June 2016

7 June 2016 – Led by Dr. Heiko Tschauner, international law firm Hogan Lovells advised US Biotech firm Myriad Genetics, a leader in molecular diagnostics and personalized medicine, on the takeover of Cologne-based Sividon Diagnostics, a leading breast cancer prognostic company.

Myriad has acquired Sividon on 31 May for €35 million upfront with the potential for €15 million in additional performance-based milestones.  Sividon Diagnostics was spun out of Siemens Healthcare Diagnostics in 2010 as part of a management buyout and subsequently financed by venture capital funds and state-owned development bank KfW. Sividon's core product, the EndoPredict® test, will be the foundational product of Myriad's newly initiated kit-based strategy and allow Myriad to leverage its global oncology distribution to bring this important test to patients worldwide.

"The Sividon acquisition is a milestone for Myriad's new kit-strategy. We are happy that we could support Myriad Genetics with this strategically important and demanding legal transaction," said Dr. Heiko Tschauner.

Hogan Lovells for Myriad Genetics:

Dr. Heiko Tschauner (Partner, Finance, München);
Dr. Ingmar Dörr (Partner, Tax, München);
Peter Huber (Counsel), Florian von Kampen (Associate, Corporate/M&A, München);
Dr. Benjamin Schroeer (Counsel, IP, München).

The team

 
Loading data